PulseAugur
EN
LIVE 13:21:32
ENTITY Ivonescimab

Ivonescimab

PulseAugur coverage of Ivonescimab — every cluster mentioning Ivonescimab across labs, papers, and developer communities, ranked by signal.

Show in brief
Total · 30d
1
1 over 90d
Releases · 30d
0
0 over 90d
Papers · 30d
0
0 over 90d
TIER MIX · 90D
SENTIMENT · 30D

1 day(s) with sentiment data

RECENT · PAGE 1/1 · 1 TOTAL
  1. TOOL · CL_63482 ·

    Akeso's lung cancer drug shows 34% reduced death risk in trials

    Akeso's lung cancer drug, ivonescimab, has shown significant promise in phase three clinical trials, reducing the risk of death by 34%. The drug demonstrated a notable survival benefit, with 64.7% of patients alive afte…